General Information of Drug (ID: DMPDTG0)

Drug Name
Imidazo[1,2-b]pyridazine derivative 3 Drug Info
Synonyms PMID28270010-Compound-Figure22-3
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Patented [1]
Cross-matching ID
TTD Drug ID
DMPDTG0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [5]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [6]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [7]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [8]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Ros (ROS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [10]
Lorlatinib DMICDLV Non-small-cell lung cancer 2C25.Y Approved [4]
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
AB-106 DMEW62S Non-small-cell lung cancer 2C25 Phase 2 [11]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
Carboxamide derivative 4 DMU5GKC N. A. N. A. Patented [12]
Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW Solid tumour/cancer 2A00-2F9Z Patented [1]
PMID28270010-Compound-Figure21-b DM6IYAT Brain metastases 2D50 Patented [1]
Imidazo[1,2-b]pyridazine derivative 1 DMULTAI Solid tumour/cancer 2A00-2F9Z Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [1]
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [1]

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
8 National Cancer Institute Drug Dictionary (drug id 747694).
9 National Cancer Institute Drug Dictionary (drug id 766123).
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
11 Clinical pipeline report, company report or official report of AnHeart Therapeutics.
12 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.